Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Curcumin, the principal curcuminoid derived from the spice turmeric (Curcuma longa), has been investigated for its therapeutic potential in Inflammatory Bowel Disorders (IBD), including Crohn’s disease and ulcerative colitis. The use of curcumin for IBD is justified by a growing body of scientific evidence, although it is not yet a mainstream treatment. Several preclinical studies have demonstrated that curcumin possesses anti-inflammatory, antioxidant, and immunomodulatory properties, which are highly relevant to the pathophysiology of IBD. It has been shown to inhibit key inflammatory mediators, such as NF-κB, TNF-α, and various interleukins, thereby reducing intestinal inflammation in animal models.

Clinical evidence, while still emerging, is promising but not definitive. Multiple randomized, placebo-controlled trials have suggested that curcumin, when used as an adjunct to conventional therapies (such as mesalamine), may help induce and maintain remission in patients with ulcerative colitis. For example, a 2006 double-blind, placebo-controlled trial published in Clinical Gastroenterology and Hepatology found that patients taking curcumin alongside standard therapy had significantly lower relapse rates than those on placebo. However, studies in Crohn's disease are fewer and less conclusive.

Overall, curcumin is supported by moderate-quality scientific evidence for use in ulcerative colitis, but more large-scale, long-term trials are needed to firmly establish efficacy and safety, particularly in Crohn’s disease. The evidence does not yet warrant routine use as a sole therapy, but it is a reasonable adjunctive option for some patients under medical supervision.

More about curcumin
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by curcumin

Products containing curcumin

Nature's Sunshine Turmeric Curcumin (Formerly CurcuminBP)